Zhu, Huiyi

  • Vol 37, No 10 (2023) - Article
    Raltegravir Plus Nucleoside Reverse-Transcriptase Inhibitor (NRTI) Plus Lopinavir, NRTIs Plus Lopinavir for Second-Line Treatment of HIV: 96-Week Follow-up Results from a Randomized Controlled Trial
    Abstract